Is XJH05 Ointment Effective for Plaque Psoriasis?

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective interventional study will evaluate the safety and potential benefit of a topical XJH05 ointment in adults with mild-to-moderate plaque psoriasis. Participants will apply XJH05 or a calcipotriol ointment to affected skin, with outcomes focused on symptom changes and local tolerance. The investigation builds on preclinical data suggesting the XJH05 compound disrupts a signaling axis involved in skin inflammation and keratinocyte growth. Recruitment is limited to sites at Xijing Hospital in Xi’an, China, and follows standard topical-therapy washout and safety monitoring protocols.

Why it matters

Who can join: the full rules

1. Inclusion Criteria:

   * Diagnosis of plaque psoriasis.
   * Mild-to-moderate disease presentation suitable for topical intervention (e.g., ≤2% to 10% BSA).
   * Provision of written informed consent prior to study procedures.
2. Exclusion Criteria:

   * Non-plaque subtypes (e.g., erythrodermic, pustular, or generalized guttate psoriasis).
   * Recent use of systemic antipsoriatic therapies, biologics, or topical steroids/retinoids within the protocol-defined washout period.
   * Active localized skin infection at target sites or known hypersensitivity to XJH05 or ointment ingredients.

Where it's running

• Department of Dermatology, Xijing Hospital, Air Force Medical University
  Xi'an, Shaanxi, China Recruiting

Study contacts

• Study coordinator: Yunfeng Gu
• Email: guyunfengzyx@163.com
• Phone: 17778914020

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HB0017 Injection safety and PK in low-weight adults at different injection sites

  This early-phase study tests a single subcutaneous HB0017 injection in healthy, low-weight adults and compares how the body processes the drug when injected at different sites.

  Recruiting Phase 1 Huabo Biopharm Co., Ltd. · Hangzhou, Zhejiang · NCT07920861

• Retinal Vessel Density and Foveal Avascular Zone Size in Psoriatic Arthritis

  This study tests whether retinal blood vessel density and the size of the foveal avascular zone differ between people with psoriatic arthritis, people with psoriasis, and healthy individuals using non-invasive eye imaging.

  Recruiting Bursa Yuksek Ihtisas Training and Research Hospital · Bursa, Yıldırım · NCT07858591

• MK-8644: first-in-human test in healthy people and people with psoriasis

  This early-phase study tests MK-8644 versus placebo in healthy volunteers and people with psoriasis to see if it is safe and tolerable.

  Recruiting Phase 1 Merck Sharp & Dohme LLC · Melbourne, Victoria · NCT07850310

• Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care

  This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.

  Recruiting Janssen-Cilag Kft. · Budapest · NCT07746583

• HL40626S tablets in healthy adults: a first-in-human dose study

  This Phase 1 study tests HL40626S tablets in healthy adults to see if it is safe, tolerated, and how it behaves in the body after single and 14-day multiple doses.

  Recruiting Phase 1 HighsLab Therapeutics Inc. · Melbourne, Victoria and 1 other locations · NCT07736586

• TQH3906 capsules vs warmer options in adults with moderate to severe plaque psoriasis

  This Phase 3 trial tests whether once-daily TQH3906 capsules can help adults with moderate to severe plaque psoriasis better than a placebo or the active drug deucravacitinib.

  Recruiting at 13 sites Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 44 other locations · NCT07724366

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.